UPDATE : Monday, June 1, 2020
상단여백
Celltrion secures 11 generic drugs to advance to US market
Celltrion said it is speeding up efforts to enter into the U.S. market afte...
by Lee Han-soo  |  2019-12-16 17:02
라인
Helixmith to clarify why gene therapy study had data error
Helixmith said it would announce next month the cause of the data error in ...
by Jeong Sae-im  |  2019-12-13 15:13
라인
Yuhan to start phase-3 trial on lung cancer drug Lazertinib
Yuhan Corp. said it would start a phase-3 global study to evaluate the effi...
by Jeong Sae-im  |  2019-12-12 15:04
라인
Aprogen, 1st Korean biotech firm to win unicorn status
Aprogen has joined the list of unicorn companies, as the first Korean biote...
by Jeong Sae-im  |  2019-12-11 13:10
라인
Samsung Bioepis to start P3 trial for Ontruzant in China
Samsung Bioepis said that China’s National Medical Products Administration ...
by Lee Han-soo  |  2019-12-10 14:16
라인
Samsung execs get jail term for destroying evidence
A Seoul court gave jail terms to Samsung executives for destroying evidence...
by Jeong Sae-im  |  2019-12-10 11:43
라인
Celltrion unveils long-term P3 trial results for Truxima in US
Celltrion said that it has presented the long-term follow-up results of its...
by Lee Han-soo  |  2019-12-09 10:36
라인
Celltrion 1st Korean biopharmaceutical firm to achieve $1-billion exports
Celltrion Healthcare said that it has become the first local biopharmaceuti...
by Lee Han-soo  |  2019-12-05 15:04
라인
Alteogen inks licensing-out deal for SC injection formulation technology
Alteogen, a biotech firm, said it has successfully concluded a deal to make...
by Jeong Sae-im  |  2019-12-02 15:25
라인
Kolon Life Science’s research head arrested for false Invossa data
A Seoul court issued an arrest warrant for an executive at Kolon Life Scien...
by Jeong Sae-im  |  2019-11-28 11:18
라인
FDA begins to review Samsung Bioepis' anticancer biosimilar application
Samsung Bioepis headquarters in Songdo, Incheon. Samsung Bioepis said tha...
by Lee Han-soo  |  2019-11-20 15:10
라인
Vivozon’s acquisition of Lumimicro may aim at backdoor listing
Vivozon, a privately held biopharmaceutical firm on the over-the-counter (O...
by Jeong Sae-im  |  2019-11-20 14:44
라인
ABL Bio, Genscript to cooperate on bispecific antibodies
ABL Bio said that it would co-develop new bispecific antibodies with Genscr...
by Lee Han-soo  |  2019-11-19 17:18
라인
Will Biogen be 1st to get FDA nod for Alzheimer’s drug?
Biogen recently unveiled the new results of studies on aducanumab, an inves...
by Kim Yun-mi  |  2019-11-14 11:23
라인
How can Korean drugmakers enter Europe successfully?
Officials from the Korea Pharmaceutical and Bio-Pharma Manufacturers Associ...
by Jeong Sae-im  |  2019-11-13 15:22
라인
Samsung Bioepis expects ₩1 trillion biosimilar sales this year
Samsung Bioepis said it was confident of achieving 1 trillion won ($855.8 m...
by Jeong Sae-im  |  2019-11-13 15:21
라인
[News Focus] ‘FDA could allow resumption of Invossa trial’
Amid the prosecution’s probe into Kolon Life Science’s osteoarthritis gene ...
by Jeong Sae-im  |  2019-11-12 15:48
라인
Celltrion marks robust Q3 sales
Celltrion said that it has recorded sales of 289.1 billion won ($249 millio...
by Lee Han-soo  |  2019-11-07 14:03
라인
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates
Samsung Bioepis said the company would strengthen its partnership with Biog...
by Lee Han-soo  |  2019-11-07 11:16
라인
Court rejects arrest warrant for 2 Kolon execs
A local court has refused to issue an arrest warrant against two executives...
by Jeong Sae-im  |  2019-11-05 13:54
여백
여백
여백
Back to Top